<DOC>
	<DOCNO>NCT01467505</DOCNO>
	<brief_summary>To assess efficacy telaprevir , pegylated interferon alfa-2a ( Peg-IFN-alfa-2a ) , ribavirin ( RBV ) hepatitis C virus ( HCV ) 48-week total treatment duration regimen follow liver transplantation .</brief_summary>
	<brief_title>An Open Label Study Effect Telaprevir Combination With Ribavirin Peginterferon HCV Infection Stable Liver Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Male female participant age 18 65 year History orthotopic liver transplantation le 10 year Screening visit sooner 6 month Day 1 Taking stable immunosuppressant regimen base either tacrolimus cyclosporine without substantial dose change past 3 month Naive pegylated interferon/ribavirin treatment experience pegylated interferon/ribavirin prior transplantation relapse , partial , null response Documented cirrhosis liver transplantation Ascites hepatic encephalopathy within 6 month Screening Retransplantation recurrent hepatitis C Treatment hepatitis C post liver transplantation History within past 3 month : rejection within 3 month great ( &gt; ) 1 rejection within 12 month Current treatment sirolimus methylprednisolone . Low dose prednisone use ( &lt; 5 milligram per day ) permit History within 3 month bacterial infection require &gt; 1 week intravenous antibiotic , cytomegalovirus viremia cytomegalovirus infection endorgan involvement , fungal disease ( except cutaneous mild oral thrush ) History post transplant lymphoproliferative disease Acceptable laboratory value Screening specify protocol Positive human immunodeficiency virus 1/2 ( HIV1/2 ) enzyme immunoassay ( EIA ) antibody screen Hepatitis B deoxyribonucleic acid ( DNA ) Hepatitis B surface antigen History hepatocellular carcinoma high risk recurrence Any cause liver disease deem clinically significant investigator addition hepatitis C Autoimmunemediated disease History acute pancreatitis within 5 year Screening visit Prior treatment hepatitis C virus ( HCV ) protease inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>